Mycobacterium leprae DNA in peripheral blood may indicate a bacilli migration route and high-risk for leprosy onset  by Reis, E.M. et al.
Mycobacterium leprae DNA in peripheral blood may indicate a bacilli
migration route and high-risk for leprosy onset
E. M. Reis1,2, S. Araujo1,2, J. Lobato1, 3, A. F. Neves4, A. V. Costa1, M. A. Goncalves1, L. R. Goulart5,6 and I. M. B. Goulart1,2
1) National Reference Centre for Sanitary Dermatology and Leprosy, Clinic Hospital, Federal University of Uberlandia, Uberlandia, 2) Post-Graduation Programme
in Health Sciences, School of Medicine, Federal University of Uberlandia, Uberlandia, 3) Institute of Biomedical Sciences, Federal University of Uberlandia,
Uberlandia, MG, 4) Federal University of Goias, Catalao, GO, 5) Institute of Biochemistry and Genetics, Federal University of Uberlandia, Uberlandia, MG, Brazil
and 6) Department of Medical Microbiology and Immunology, Genome and Biomedical Sciences Facility, University of California, Davis, CA, USA
Abstract
Leprosy epidemiological studies have been restricted to Mycobacterium leprae DNA detection in nasal and oral mucosa samples with scarce
literature on peripheral blood. We present the largest study applying quantitative real-time PCR (qPCR) for the detection of M. leprae DNA
in peripheral blood samples of 200 untreated leprosy patients and 826 household contacts, with results associated with clinical and
laboratory parameters. To detect M. leprae DNA a TaqMan qPCR assay targeting the M. leprae ML0024 genomic region was performed.
The ML0024 qPCR in blood samples detected the presence of bacillus DNA in 22.0% (44/200) of the leprosy patients: 23.2% (16/69) in
paucibacillary (PB), and 21.4% (28/131) in multibacillary (MB) patients. Overall positivity among contacts was 1.2% (10/826), with similar
percentages regardless of whether the index case was PB or MB. After a follow-up period of 7 years, 26 contacts have developed leprosy.
Comparing the results of healthy contacts with those that become ill, ML0024 qPCR positivity at the time of diagnosis of their index case
represented an impressive 14.78-fold greater risk for leprosy onset (95% CI 3.6–60.8; p <0.0001). In brief, contacts with positive PCR in
blood at diagnosis of index cases are at higher risk of later leprosy onset and this marker might be combined with other prognostic markers
for management of contacts, which requires further studies.
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Introduction
Leprosy is a complex disease caused by Mycobacterium leprae,
an obligate intracellular pathogen with tropism for Schwann
cells and cells of the mononuclear phagocyte system. The
disease has a wide variety of clinical presentations which are
classiﬁed into a spectrum of clinical forms according to the
patient’s immunological status; two polar forms, tuberculoid
(TT) and lepromatous (LL) leprosy, and three unstable
borderline groups: borderline-tuberculoid (BT), borderline-
borderline (BB) and borderline-lepromatous (BL) [1]. The
tuberculoid side of the spectrum (TT and BT leprosy) is
characterized by vigorous cell-mediated immune response,
well-deﬁned skin and nerve lesions, and few bacilli (pauciba-
cillary leprosy, PB). Across the ﬁve-group system, the host
presents gradual reduction of cell-mediated immune
responses towards the lepromatous side of the spectrum
(BL and LL), associated with increased bacillary load, several
skin and nerve lesions, and high antibody titres (multibacillary
leprosy, MB) [2].
Untreated MB patients are considered the main source of
M. leprae transmission [3,4]. However, the number of MB
patients is small and cannot represent the sole source of
infection. Currently, the possibility of bacilli spread is not
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restricted to leprosy patients, healthy carriers and individuals
with subclinical infections, i.e. household contacts who carry
M. leprae in their nasal [4–7] and or oral mucosa [8], may play
an important role in the disease chain of transmission.
Detection of M. leprae DNA by conventional PCR has
achieved signiﬁcant sensitivity and speciﬁcity when compared
with conventional bacilli staining techniques [9–11]. However,
quantitative real-time PCR (qPCR) has displayed even higher
sensitivity and speciﬁcity in diagnosis of several parasites, and
has been successfully applied to detect M. leprae DNA, mainly
in skin smears and biopsy samples [8,12,13].
Clinical signs of leprosy are most commonly observed in
the skin and peripheral nerves, but it is suggested that
bacteraemia may occur at some point during disease progres-
sion [14]. The presence of M. leprae in peripheral blood has
not been thoroughly investigated, although some reports have
shown an infrequent presence of M. leprae in the blood of
leprosy patients using both staining techniques [14] and
conventional PCR [3]. At this time there are no publications
on the qPCR detection of M. leprae DNA in peripheral blood
samples.
It is necessary to deﬁne if besides indicating subclinical
infection, M. leprae DNA in blood may represent a risk factor
for leprosy development in these individuals. This study aims
to evaluate the presence of M. leprae DNA in peripheral
blood samples of leprosy patients and their household
contacts.
Materials and Methods
Assays were performed in peripheral blood samples of 200
untreated leprosy patients and 826 household contacts
attending the National Reference Centre for Sanitary Derma-
tology and Leprosy (CREDESH), MG, Brazil. Research proto-
col was approved by an independent research ethics
committee and participants signed an informed consent form.
Study subjects
All leprosy patients were diagnosed by a committee of leprosy
experts based on clinical and laboratory tests and were
classiﬁed according to the Ridley–Jopling clinical forms ﬁve-
group system (TT, BT, BB, BL, LL). For treatment purposes, all
patients also received an operational classiﬁcation into PB or
MB [2].
Blood samples were collected from all patients at diagnosis
and all underwent: Mitsuda test, an intradermal injection of
0.1 mL of a heat-killed M. leprae suspension of 6 9 107
bacilli/mL produced by the Lauro de Souza Lima Institute
(ILSL-SP), with results observed 28 days later and stratiﬁed
according to the measurement in millimetres of the nodular
epithelioid granuloma diameter: negative (0–3 mm), weakly
positive (4–7 mm), positive (8–10 mm), strongly positive
(>10 mm or of any size with ulceration); bacillary index in
skin smears and bacillary index in skin lesion biopsies, with
positive results when any bacilli were observed and negative
when none were found; and anti-phenolic glycolipid-1
(PGL-1) ELISA, an indirect ELISA to detect antibodies against
the M. leprae native PGL-1 molecule (donated by Dr John
Spencer, Colorado State University, CO, USA), performed
with a protocol standardized and previously described by our
research group [15].
The CREDESH database holds records of 3113 contacts
enrolled in the period from 2002 to 2012. A follow-up period
of 7 years was established as sampling criterion and only
contacts with a complete set of clinical and laboratory
parameters were included, totalling 826 contacts.
These 826 household contacts were stratiﬁed according to
clinical forms and operational classiﬁcation of their index case.
All the contacts were examined by specialist leprosy physi-
cians for signs or symptoms that were suggestive of leprosy
and all displayed normal dermato-neurological clinical exam-
inations. Blood samples were collected from all contacts at
diagnosis of their index case and they also underwent Mitsuda
test and anti-PGL-1 ELISA. Contacts were further stratiﬁed
into two classes: affected (those who develop leprosy) and
healthy (those without any sign or symptom). Table 1
summarizes these assessments of leprosy patients and house-
hold contacts.
DNA extraction and qPCR
DNA from 500 lL peripheral blood was extracted with
phenol and precipitated with ethanol. At the end, the DNA
pellet was dried at room temperature and suspended in 50 lL
ultrapure water.
A region of 69 bp from a unique M. leprae genomic region
(Gene: ML0024—GenBank Accession no. AL583917) was
ampliﬁed, detected and quantiﬁed using a TaqMan primer/
probe assay as previously described [8].
Statistical analysis
Differences between the groups were assessed by chi-squared
or Student’s t-test, when appropriate. The kappa test was
applied to evaluate the agreement between the ML0024 qPCR
and other tests. Pearson’s linear correlation test was
employed to assess the correlation between ML0024 qPCR
and other tests. The OR and positive likelihood ratio were
calculated to evaluate the performance of tests and estimate
the probabilities for later leprosy onset. Statistical signiﬁcance
was set at p <0.05.
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Results
TheM. leprae qPCR in blood samples detected the presence of
bacillary DNA in 22.0% (44/200) of leprosy patients: 23.2% (16/
69) in PB patients, and 21.4% (28/131) in MB patients.
The ML0024 qPCR positivity assessed according to the
patient’s clinical form ranged from 16% (4/25) for TT to 33.3%
(11/33) for LL patients (Table 1).
Among the 44 patients with positive ML0024 qPCR, 59%
(26/44) were positive for anti-PGL-1 ELISA, and 72% (32/44)
had negative or weakly positive Mitsuda response.
The Kappa values obtained between the ML0024 qPCR and
the tests mentioned were lower than 0.04, revealing lack of
agreement.
The qPCR quantiﬁcation of bacillary load in blood samples
revealed values ranging from 870 up to 5.94 9 105 ML0024
DNA copies per mL of blood, which corresponds to TT and
LL values, respectively. The average number of DNA copies
did not show a direct relationship with the spectrum of clinical
forms, nor with the operational classiﬁcation (PB or MB).
Among household contacts, 1.2% (10/826) were positive for
ML0024 qPCR in peripheral blood. DNA was detected in 1.1%
(2/182) of contacts of PB patients and in 1.2% (8/644) of
contacts of MB patients (Table 1).
A high statistical signiﬁcance was observed between the
ML0024 qPCR positivity in blood of leprosy patients and
household contacts (p <0.0001).
All household contacts (10/10) with positive ML0024 qPCR
also presented negative Mitsuda tests or weakly positive (0–
7 mm) (p 0.0131) and 40% (4/10) were positive for anti-PGL-1
ELISA (p 0.1283).
The contacts were followed up for a period of 7 years. In
this period, 3.1% (26/826) developed leprosy, all of them were
contacts of MB patients and 61.5% (16/26) were contacts of LL
patients. Among these 26 contacts, ML0024 qPCR detected
DNA from M. leprae in 11.5% (3/26), the ELISA test was
positive in 57.7% (15/26), and Mitsuda test was negative or
weakly positive in 84.6% (22/26).
The sensitivity and speciﬁcity parameters obtained for
ML0024 qPCR in the blood of household contacts were 11.5%
(3/26) and 99.1% (793/800), respectively. The ML0024 qPCR
positivity among contacts presented an impressive OR of
14.78-fold towards leprosy development (95% CI 3.6–60.8;
p <0.0001), and positive likelihood ratio of 13.19 (95% CI: 3.6–
48.1; p <0.0001). The anti-PGL-1 ELISA positivity presented
TABLE 1. Laboratory tests results according to clinical forms and operational classiﬁcation of leprosy patients and index cases of
household contacts
Laboratory tests
Patients (n = 200)
Operational classiﬁcation and clinical form
PB (n = 69) MB (n = 131)
TT (n = 25) BT (n = 44) BT (n = 34) BB (n = 34) BL (n = 30) LL (n = 33)
n % n % n % n % n % n %
BI in skin biopsies positivity 1 4 8 18.2 19 55.9 23 67.7 28 93.3 32 97
BI in skin smears positivity 0 0 0 0 2 5.9 33 97.1 30 100 33 100
Mitsuda test positivity 23 92 40 90.9 15 44.1 1 2.9 0 0 0 0
Average Mitsuda (mm)  SD 9.9  2.5 6.6  2.8 3.1  3.2 0.5  1.4 0  0 0  0
Anti-PGL-1 ELISA positivity 0 0 10 22.7 21 61.8 30 88.2 29 96.7 33 100
Average ELISA index  SD 0.5  0.3 0.8  0.8 2.9  3.4 4.9  3.9 7.2  5.1 7.8  5.7
ML0024 qPCR positivity 4 16 12 27.3 6 17.6 5 14.7 6 20 11 33.3
Laboratory tests Household contacts (n = 826)
Operational classiﬁcation and clinical form of index case
PB (n = 182) MB (n = 644)
TT (n = 60) BT (n = 122) BT (n = 160) BB (n = 144) BL (n = 130) LL (n = 210)
n % n % n % n % n % n %
Mitsuda test positivity 54 90 111 91 141 88.1 135 93.7 115 88.5 184 87.6
Average Mitsuda (mm)  SD 8.1  4.4 7.0  3.0 7.7  3.5 7.7  3.6 6.9  3.3 6.9  3.4
Anti-PGL-1 ELISA positivity 8 13.3 15 12.3 25 15.6 24 16.7 19 14.6 47 22.4
Average ELISA index  SD 0.6  0.4 0.6  0.4 0.7  0.5 0.8  1.3 0.7  0.6 1.2  5.5
ML0024 qPCR positivity 1 1.7 1 0.8 0 0 1 0.7 2 1.5 5 2.4
PB, paucibacillary; MB, multibacillary; TT, tuberculoid; BT, borderline tuberculoid; BB, borderline; BL, borderline lepromatous; LL, lepromatous leprosy; BI, bacterial index; SD,
standard deviation; PGL-1, phenolic glycolipid 1.
For anti-PGL-1, considered positive result: ELISA index ≥ 1.1.
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7.51-fold higher risk of becoming ill (95% CI 3.4–16.7;
p <0.0001); whereas the positive Mitsuda test (>7 mm)
showed a 4.35-fold greater chance of protection (OR 0.23;
95% CI 0.08–0.66; p 0.0058) (Table 2).
Discussion
The present study is the largest study to evaluate the presence
of M. leprae DNA in peripheral blood samples of leprosy
patients and household contacts. We have shown that the
presence of M. leprae DNA in blood indicates a higher risk for
leprosy development in contacts, which suggests a likely path of
the infection process, after its passage through the mucosa of
the upper respiratory tract and before the impairment of the
peripheral nervous system. This infection process implicates a
transient passage of bacilli through the bloodstream; almost
one-quarter of patients presented positive PCR. However, the
limitations of this study are the lack of multiple samples from
the same individual collected at the same time and at different
time-points, to demonstrate whether variability of bacterial
DNA detection is due to sampling or to its microenvironmen-
tal requirements, which must be further investigated.
PCR positivity presented no correlation with clinical forms,
anti-PGL-1 ELISA, bacillary index, and Mitsuda test. Neverthe-
less, LL patients presented twice the frequency and higher
bacterial load than observed in TT patients. It is debatable
whether bacilli should not be expected in tuberculoid forms of
the disease, as macrophages would kill and degrade the
bacillus, including DNA, but M. leprae is an obligate intracel-
lular pathogen that invades and multiplies within host mono-
nuclear phagocytes, and immature monocytes can be
reservoirs of fully viable DNA during M. leprae blood migra-
tion, a cellular event that seems to be required before the
infection of Schwann cells and tissue macrophages.
The complete mechanism of infection of M. leprae is still
unknown, but evidence of nasal and oral mucosa as entry sites
have been provided [6–8,16]. Authors of the ﬁrst seminal
publication that found M. leprae in the peripheral blood of LL
patients have suggested that bacilli may be continuously
present, but it may decrease during treatment [14]. Similarly,
the detection of M. leprae DNA in nasal swabs of household
contacts [4] reduced from 4% to 0% when the index case in
each household was treated for 2 months, showing that
effective MDT decreases repeat infection within the house-
hold.
Although the speciﬁcity of the PCR test in the blood was
very high (99.1%), the sensitivity was low (11.5%), and no test
alone would be worthwhile with such a low sensitivity, unless
combined with other tests to bolster the leprosy diagnosis. It
is relevant to emphasize that blood is not the best sample for
the diagnostic detection of M. leprae, its regular temperature
around 37°C does not constitute a suitable environment for
the development and survival of M. leprae. The bacillus is
presumably detected in the blood during the short period in
which the infected cells migrate to the extremities of the body,
where temperature ranges from 30 to 35°C, which favours
M. leprae reproduction [17].
The presence of up to 105 viable leprosy bacilli/mL of blood
both reﬂects and helps to explain the extreme widespread
nature of M. leprae infection in patients with lepromatous
leprosy [18]. The high titres of M. leprae-speciﬁc antibodies,
although prevalent in LL leprosy patients, do not provide
protection [19], and these factors may favour blood dissem-
ination of the bacillus and its detection.
On the other hand, the speciﬁc immune cellular response
observed among TT leprosy patients plays an important role
against bacillary proliferation and dissemination, conﬁning the
bacillus to a few areas of the skin and/or nerves [17]. At the
same time, PCR positivity observed in TT and BT patients
might also imply an ongoing attack to the reticuloendothelial
system and the recirculation of infected phagocytes into the
bloodstream, which may account in part for the intermittent
nature of leprosy bacteraemia [14].
Two studies have addressed the detection of M. leprae
DNA in blood through conventional PCR. One of these
TABLE 2. Assessment of results for
ML0024 qPCR, anti-PGL-1 ELISA,
and Mitsuda tests based on the pos-
itivity at diagnosis of the index case
observed in healthy household con-
tacts (n = 800) in comparison with
those contacts that were affected by
leprosy (n = 26)
Test and type of
contact
No. of
positives
No. of
negatives
Diagnostic
parameters OR (95% CI) LR+ (95% CI)
ML0024 qPCR
Affected 3 23 Sensitivity 11.5% 14.78 (3.6–60.8) 13.19 (3.6–48.1)
Healthy 7 793 Speciﬁcity 99.1%
Anti-PGL-1 ELISAa
Affected 15 11 Sensitivity 57.7% 7.51 (3.4–16.7) 3.75 (2.6–5.4)
Healthy 123 677 Speciﬁcity 84.6%
Mitsuda testb
Affected 4 22 Sensitivity 15.4% 0.23 (0.08–0.66) 0.34 (0.14–0.85)
Healthy 357 443 Speciﬁcity 55.4%
LR+, positive likelihood ratio; PGL-1, phenolic glycolipid 1.
aFor anti-PGL-1, considered positive result: ELISA index ≥ 1.1
bFor Mitsuda test, considered positive result: node > 7 mm.
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evaluated leprosy patients 8 years after MDT and observed
70.6% (12/17) positivity [20]. Having been conducted in an
endemic area, the hypothesis of re-infection or relapse cannot
be excluded, and a selection bias, due to the small number of
patients evaluated, could not be ruled out. The second study
evaluated 119 household contacts and observed 1.7% (2/119)
positivity [9], which corroborates with 1.2% positivity observed
in the present study, suggesting a similar PCR efﬁciency,
especially considering that our sampling was eight times larger.
The percentage ofM. lepraeDNA in peripheral blood samples of
household contacts was 18 times lower than that among
patients, similar to other studies that applied conventional PCR
followed by a 32P-labelled probe hybridization [9].
Recently, the M. leprae-speciﬁc repetitive sequence marker
which targets an invariant region of the RLEP noncoding
chromosomal element of dispersed repeats, has been shown
to be more sensitive than other primer sets of unique
alignment [11], most likely because its repetitive sequence is
presented several times in the genome. Perhaps, a qPCR
targeting RLEP sequence, which detects very low levels of
DNA, would provide higher positivity rates in peripheral
blood.
All PCR-positive contacts also presented negative or weakly
positive Mitsuda test results, suggesting that besides the
prognostic value, the immune cellular response cooperates in
the early resistance against bacillary invasion of the mucosa.
The comparison of the presence of M. leprae DNA in the
blood of contacts and the development of leprosy in this group
showed an impressive 14.78-fold association between positive
PCR and later disease onset. Besides that, the fact that all
those who became ill were contacts of MB patients supports
the theory that contacts of MB patients are at greater risk for
the development of leprosy [21–23].
The small percentage of PCR positivity among contacts can
disclose an important public health issue. Considering the
latest ofﬁcial data of 219 075 new cases detected in the world
[24] and an average of four household contacts per patient,
this leads to an estimate of 876 300 household contacts of
leprosy patients, and assuming the 1.2% PCR positivity in this
group of individuals, it could be considered that 10 515
household contacts worldwide have M. leprae DNA in their
bloodstream and are at greater risk of becoming ill.
Two publications [3,18] have shown that viable bacilli,
potentially infective, were isolated from the peripheral blood
of untreated leprosy patients, as judged by their capacity to
multiply in the mouse footpad. However, because of the long-
term test in mouse footpad with a restricted sensitivity, the
detection of M. leprae mRNA through reverse transcription
PCR may be a good option to evaluate the viability of blood-
borne bacilli.
The carriage of bacilli in the blood of contacts in conjunc-
tion with greater chances for leprosy development in PCR-
positive contacts are additional evidence of subclinical infection
and those individuals without symptoms may behave as healthy
carriers with a potential role in the chain of transmission of
leprosy in endemic regions.
These ﬁndings have important implications for disease
management and clinical practice. The concomitant use of
tools to detect M. leprae DNA in the blood, anti-PGL-1
circulating antibodies and the Mitsuda test, will allow us to
identify high-risk individuals, justifying the chemoprophylaxis
of close contacts of leprosy patients who ﬁt the highest-risk
categories in this study, as has been suggested elsewhere
[25].
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